In Q3 FY2026 (ended March 31, 2026), ResMed reported revenue of $1.43 billion, up 10.8% year-over-year. Net income rose 9.2% to $398.7 million, while operating income increased 17.3% to $499.8 million. Diluted EPS grew 10.5% to $2.74. The company held $1.66 billion in cash and $4.04 billion in long-term debt, with equity of $6.49 billion.
•Revenue of $1.43B (+10.8% YoY)
•Net income of $398.7M (+9.2% YoY)
•Operating income of $499.8M (+17.3% YoY)
•Diluted EPS of $2.74 (+10.5% YoY)
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
ResMed develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and globally.
The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home Including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring.
Its portfolio also includes NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry, and EasyCare Tx, a sleep lab solution AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings.
Its portfolio also includes myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance, and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system.
Additionally, it offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion.
Its portfolio also includes HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes, MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors, and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. Founded in 1989, ResMed is headquartered in San Diego, California.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for diagnosing, treating, and managing respiratory disorders. The company operates in two segments: Sleep and Breathing Health, and Residential Care Software. Its products include sleep recorders like ApneaLink Air for diagnosing sleep apnea, portable diagnostic devices like NightOwl, and cloud-based systems such as AirView for remote patient monitoring. ResMed also offers patient engagement tools like myAir and connectivity modules for ventilation devices. Additionally, through Brightree and HEALTHCAREfirst, it provides software, billing, and analytics solutions for home medical equipment, home health, and hospice organizations.
Where is ResMed (RMD) listed and in what currency?
ResMed Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol RMD. Its shares are traded in US Dollars (USD). The company is headquartered in the United States and operates globally, with its primary listing on a major US exchange, making it accessible to investors in the American market and internationally.
What sector and industry does ResMed (RMD) belong to?
ResMed Inc. operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. This means the company focuses on producing medical devices and related software used by healthcare providers and patients. Its products are designed to diagnose and manage respiratory conditions, particularly sleep apnea, and support home healthcare services through software solutions.
Where is ResMed (RMD) headquartered and what markets does it serve?
ResMed Inc. is headquartered in the United States and serves markets globally, including the United States and international regions. The company's products and software are used in sleep clinics, hospitals, and homes worldwide. Its cloud-based platforms like AirView and myAir enable remote monitoring and patient engagement across different geographies, while its Brightree and HEALTHCAREfirst solutions support home medical equipment and home health organizations primarily in the US.
How does ResMed (RMD) make money?
ResMed generates revenue through two main segments: Sleep and Breathing Health, and Residential Care Software. The Sleep and Breathing Health segment sells medical devices such as sleep recorders, diagnostic tools like NightOwl, and cloud-based systems for remote monitoring. The Residential Care Software segment provides software solutions, billing and coding services, and analytics for home medical equipment, orthotic and prosthetic, and home infusion organizations through Brightree, as well as electronic health record and analytics for home health and hospice via HEALTHCAREfirst. The company also offers patient engagement apps like myAir and connectivity modules for ventilation devices, creating recurring revenue streams from software and services.